Zhaohui Peng

Dr. Zhaohui Peng is the chairman, chief executive officer, and founder of Shenzhen SiBiono GeneTech Co., Ltd., Langshen Road, Shenzhen Hi-Tech Industrial Park, Shenzhen, China, 0755.2696.8818, fax: 0755.2696.8808, sbn@sibiono.com; www.sibiono.com.


Points to Consider for Human Gene Therapy and Product Quality Control State Food and Drug Administration of China

Introduction - Gene therapy is a medical intervention based on the modification of the genetic material of living cells. Currently, gene therapy is restricted in application to somatic cells.

The Genesis of Gendicine: The Story Behind the First Gene Therapy

In October 2003, Shenzhen SiBiono GeneTech made history by becoming the first company approved to market a gene therapy medication. China's State Food and Drug Administration (SFDA) approved Gendicine for treatment of head and neck squamous cell carcinoma (HNSCC). SiBiono believes that continued clinical trials will prove Gendicine to be effective as a wide-spectrum anticancer agent.